Sorafenib-induced pancreatitis

被引：24
作者：
Amar, Surabhi [1 ]
Wu, Kevin J. [1 ]
Tan, Winston W. [1 ]
机构：
[1] Mayo Clin, Coll Med, Jacksonville, FL USA
来源：
MAYO CLINIC PROCEEDINGS | 2007年 / 82卷 / 04期
关键词：
D O I：
10.4065/82.4.521
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：521 / 521
页数：1
相关论文
共 5 条
  • [1] Escudier B, 2005, J CLIN ONCOL, V23, p1093S
  • [2] PLATELET-DERIVED GROWTH-FACTOR AND TRANSFORMING GROWTH FACTOR-BETA ENHANCE TISSUE-REPAIR ACTIVITIES BY UNIQUE MECHANISMS
    PIERCE, GF
    MUSTOE, TA
    LINGELBACH, J
    MASAKOWSKI, VR
    GRIFFIN, GL
    SENIOR, RM
    DEUEL, TF
    [J]. JOURNAL OF CELL BIOLOGY, 1989, 109 (01) : 429 - 440
  • [3] Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    Strumberg, D
    Richly, H
    Hilger, RA
    Schleucher, N
    Korfee, S
    Tewes, M
    Faghih, M
    Brendel, E
    Voliotis, D
    Haase, CG
    Schwartz, B
    Awada, A
    Voigtmann, R
    Scheulen, ME
    Seeber, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) : 965 - 972
  • [4] BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Wilhelm, SM
    Carter, C
    Tang, LY
    Wilkie, D
    McNabola, A
    Rong, H
    Chen, C
    Zhang, XM
    Vincent, P
    McHugh, M
    Cao, YC
    Shujath, J
    Gawlak, S
    Eveleigh, D
    Rowley, B
    Liu, L
    Adnane, L
    Lynch, M
    Auclair, D
    Taylor, I
    Gedrich, R
    Voznesensky, A
    Riedl, B
    Post, LE
    Bollag, G
    Trail, PA
    [J]. CANCER RESEARCH, 2004, 64 (19) : 7099 - 7109
  • [5] 2006, NEVAXAR SORAFENIB PA
1